TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

April 30, 2028

Conditions
Chronic Myeloid LeukemiaAccelerated Phase CML
Interventions
DRUG

TGRX-678

All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

Shenzhen Second People's Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

Shengjing Hospital

OTHER

collaborator

Tongji Medical College,Huazhong University of Science &Techonlogy

UNKNOWN

lead

Shenzhen TargetRx, Inc.

INDUSTRY